RESUMO: Este estudo avaliou o efeito do extrato das folhas de Morus nigra, com ou sem suplementos, sobre a morfologia, a ativação e o dano ao DNA de folículos pré-antrais cultivados inclusos em tecido ovariano. Os ovários foram coletados e divididos em fragmentos, sendo um fixado para análise histológica e ensaio de marcação de terminações dUTP mediada por desoxinucleotidil transferase terminal (TUNEL) (controle fresco). Os fragmentos restantes foram cultivados durante 7 dias em meio essencial mínimo alfa (α-MEM) suplementado com albumina sérica bovina (BSA), insulina, transferrina, selênio, glutamina, hipoxantina e ácido ascorbico (α-MEM+; meio controle) ou em meio composto de extrato de M. nigra sem suplementos (0,1; 0,2 or 0,4mg/mL) ou suplementado com as mesmas substâncias descritas para α-MEM+ (MN 0,1+; 0,2+ or 0,4+mg/mL). Então, os tecidos foram destinados à análise histológica e TUNEL. O tratamento do α-MEM+ apresentou mais folículos morfologicamente normais que todos os tratamentos do extrato de M. nigra. No entanto, o tratamento com α-MEM+ também mostrou sinais de atresia, pois a porcentagem de células TUNEL positivas foi semelhante em α-MEM+ e em 0,1mg/mL M. nigra sem e com suplementos. Além disso, observou-se uma redução nos folículos primordiais e um aumento nos folículos em crescimento em todos os tratamentos, exceto 0,2mg/mL M. nigra. Em conclusão, os folículos cultivados com 0,1mg/mL de extrato de M. nigra estavam em boas condições e aptos a continuar seu desenvolvimento, como demonstrado pelas taxas de dano ao DNA e de ativação folicular semelhantes ao meio controle.

ABSTRACT: This study evaluated the effect of Morus nigra leaf extract, with or without supplementation, on morphology, activation and DNA damage of preantral follicles cultured within sheep ovarian tissue. Ovaries were collected and divided into fragments, being one fixed for histological and Terminal deoxynucleotidyl transferase (TdT) mediated dUTP nick-end labeling (TUNEL) analysis (fresh control). The remaining fragments were cultured for 7 days in alpha minimum essential media (α-MEM) supplemented with bovine serum albumin (BSA), insulin, transferrin, selenium, glutamine, hypoxanthine and ascorbic acid (α-MEM+; control medium) or into medium composed of M. nigra extract without supplements (0.1; 0.2 or 0.4mg/mL) or supplemented with the same substances described above for α-MEM+ (MN 0.1+; 0.2+ or 0.4+mg/mL). Then, tissues were destined to histological and TUNEL analysis. The α-MEM+ treatment had more morphologically normal follicles than all M. nigra extract treatments. However, α-MEM+ treatment also showed signs of atresia because the percentage of TUNEL positive cells was similar in α-MEM+ and in 0.1mg/mL M. nigra without and with supplements. Moreover, a reduction in the primordial follicles and an increase in the growing ones were observed in all treatments, except 0.2mg/mL M. nigra. In conclusion, the follicles cultured at 0.1mg/mL M. nigra extract were in good condition and able to continue their development, as demonstrated by the same rates of DNA damage and follicular activation as the control medium.

OBJETIVOS: descrever resistência antimicrobiana e sorotipos de cepas de pneumococo. MÉTODOS: durante 57 meses, foi conduzida uma vigilância de cepas invasivas de pneumococo de pacientes com idade <20 anos. O pneumococo foi identificado pelos testes de solubilidade da bile e optoquina. A resistência à penicilina foi avaliada com o disco de oxacilina (1µg) e, para as cepas não suscetíveis, foi determinada a concentração inibitória mínima. Provas de difusão de disco e de microdiluição em placa foram utilizadas para avaliação da resistência a outros antimicrobianos. Reação de Neufeld-Quellung foi realizada para sorotipagem. RESULTADOS: dos 70 pacientes, 57,1% eram do sexo masculino. A mediana da idade foi 1,92 anos (média 3,19 ± 3,66 anos, variando de um mês a 19,5 anos), tendo 52,9% e 81,4% dos pacientes idade <2 anos e <5 anos, respectivamente. As cepas foram isoladas do sangue (91,4%), liquor (2,9%), líquidos pleural (2,9%), peritonial (1,4%) ou de abscesso (1,4%), de pacientes com pneumonia (77,1%), febre sem sinais localizatórios (10,0%), meningite (4,3%) e outros diagnósticos (8,6%). Resistência foi detectada à penicilina (20,0%), ao sulfametoxazol-trimetoprim (65,7%), à tetraciclina (21,4%), à ofloxacina (6,3%), à eritromicina (5,7%) e à clindamicina (2,9%). Não houve resistência ao cloranfenicol ou à vancomicina. Entre as cepas não suscetíveis à penicilina, resistência absoluta foi detectada em uma, a mesma que apresentou resistência intermediária à cefotaxima. Os sorotipos mais freqüentes foram: 14 (22,9%), 5 e 6A (10,0% cada), 6B e 19F (8,6% cada), 9V, 18C e 23F (5,7% cada). Das cepas resistentes à penicilina, 71,4% pertenciam ao sorotipo 14, 14,3% aos sorotipos 6B e 19F (cada). CONCLUSÕES: das 70 cepas, 67,2% têm sorotipos incluídos na vacina pneumocócica heptavalente conjugada, assim como estão incluídos todos os sorotipos que apresentaram resistência à penicilina.

OBJECTIVE: describe the antimicrobial resistance and serotype distribution of pneumococcal strains. METHODS: in a 57-month period, a laboratory-based surveillance of invasive pneumococcal strains from patients aged < 20 years was conducted. Pneumococcus was identified by means of tests for solubility in bile and optochin. Pneumococcal resistance to penicillin was screened by 1µg oxacillin disc and minimal inhibitory concentration was determined for the strains not susceptible to penicillin. Disc diffusion and broth microdilution methods were used for surveillance of resistance to other antimicrobials. Pneumococci were serotyped by means of the Neufeld-Quellung reactions. RESULTS: of 70 patients, 57.1% were males. The mean age was 1.92 yrs (mean 3.19 + 3.66 yrs, range 1 month to 19.5 yrs); 52.9% and 81.4% were < 2 yrs and < 5 yrs, respectively. The strains were isolated from blood (91.4%), CSF (2.9%), pleural (2.9%), peritoneal (1.4%) and abscess (1.4%) fluids from patients with pneumonia (77.1%), fever without localizing signs (10.0%), meningitis (4.3%), others (8.6%). Resistance was detected to penicillin (20.0%), trimethoprim-sulfamethoxazole (65.7%), tetracycline (21.4%), ofloxacin (6.3%), erythromycin (5.7%), clindamycin (2.9%). All tested strains were susceptible to chloramphenicol and vancomycin. Among penicillin-resistant strains, high resistance was detected in one, the same that showed intermediate resistance to cefotaxime. The most frequent serotypes were: 14 (22.9%), 5 and 6A (10.0% each), 6B and 19F (8.6% each), 9V, 18C and 23F (5.7% each). Resistance to penicillin was detected in serotypes 14 (71.4%), 6B and 19F (14.3% each). CONCLUSIONS: of 70 strains, 67.2% were classified as serotypes included in the heptavalent conjugate pneumococcal vaccine as well as were all penicillin-resistant strains.

This study was a non-comparative multicenter clinical trial to evaluate the efficacy and tolerability of itraconazole oral solution 200 mg/day (100 mg twice a day in the fasting state) for the treatment of oropharyngeal candidiasis in AIDS patients. We included 50 patients who were treated and followed for up to 3 weeks after ending therapy in the analysis. Mycological cures at the end of therapy occurred in 20/50 patients (40%), but colonization by Candida sp. was recorded in 42/50 (84%) by the end of follow-up. A high rate of clinical response was observed in 46/50 (92%), and the response was sustained for up to 21 days after stopping therapy in 24/46 patients (52%). Clinical relapses were documented among 22 patients, but all causative fungal organisms associated with a relapse were susceptible to itraconazole. There were many patients with persistence or recurrence of Candida, but without mucositis. Relapse of Candida mucositis was significantly related to low levels of CD4 lymphocytes exhibited by symptomatic patients. The drug was well tolerated by all but 1 patient. We conclude that itraconazole oral solution (100 mg bid for 7-14 days) is a well tolerated and effective treatment for suppressing the symptoms of oropharyngeal candidiasis in AIDS patients. Patients with severe immunosuppression may relapse and require frequent cycles of treatment or longterm suppressive therapy.